

Multi-drug resistance pattern of *Staphylococcus aureus* from Paediatric ward, General Hospital, Ikot-Ekpaw, Mkpato Enin LGA, Akwa-Ibom State, Nigeria.

ABSTRACT - Make in format as aim, location and duration of study, design of study, result and interpretation; leave the space before mentioning of units

The evaluation of the Multi-drug resistance pattern of *Staphylococcus aureus* from a paediatric ward, in Akwa-Ibom State was conducted using standard clinical microbiological procedures. Of the 100 samples from skin, wound, ear, throat and nose swabs, 28 isolates were confirmed as *S. aureus* and were subjected to a range of selected commercially available antibiotics like: amoxicillin, ampiclox, chloramphenicol, ciprofloxacin, erythromycin, gentamicin, levofloxacin, norfloxacin, rifampicin and streptomycin, to evaluate their susceptibilities. The wound swabs gave the highest isolate percentage yield (32%) followed by skin swabs (29%). While susceptibility results showed that amoxicillin and ampiclox were more resisted by the isolates, while ciprofloxacin, levofloxacin and norfloxacin were more effective against the isolates. The MAR indices showed that 85.7% of the isolates had confirmed multi-drug resistance status, with 60.7% of the isolates having resistance for between four or more the tested antimicrobials. MAR indices revealed that 96.4% of the isolates had 0.3, indicating that the resistance resulted from isolates that adapted to the tested drugs due to some form of abuse. Restricted use of these drugs would help curtail the high resistance currently experienced amongst microorganisms.

Key words: multi-drug resistance, *Staphylococcus aureus*, multiple antibiotics resistance index, susceptibility test, nosocomial infections

INTRODUCTION – sequentially number the references mentioned in this section in square bracket

Microbes do manifest themselves in three ways, through substance spoilage, fermentation of organic and inorganic matters and causation of ailments. Different microorganisms, with their different mode of aetiology, causing different types of ailments, will require different methods and capable drugs for treatments. Continuous deployment of antimicrobial drugs in treating microbial infections has led to the emergence of resistance amongst various strains of microorganisms (McIntosh, 2018; Tanwar *et al.*, 2014). MDR literally means ‘being resistant to more than one antimicrobial agent’, although a standardized definition has not yet been agreed upon by the medical community. There are currently other definitions that are used to characterize patterns multidrug resistance. The most practical definition used for Gram-positive

37 and Gram-negative bacteria is 'resistance to three or more antimicrobial classes according to
38 Magiorakos *et al.* (2012). MDR could also be defined as the insensitivity or resistance of a
39 microorganism to administered antimicrobial medicines (which are structurally unrelated and
40 have different molecular targets) despite earlier sensitivity to the same medicines (Singh, 2013).

41 According to Nikaido (2009), multidrug resistance in bacteria cells come about by their
42 accumulation, on resistance (R) plasmids or transposons, of genes, with each coding for
43 resistance to a specific agent, and/or by the action of multidrug efflux pumps, each of which can
44 pump out more than one drug type. This MDR abilities lead to ineffective ailment treatment,
45 resulting in its persistence, infection's spread and high cost (Tanwar *et al.*, 2014; WHO, 2014).

46 The hospital environment have been said to be a active reservoir for infectious microorganisms,
47 being the meeting point for people with diverse disease etiological agents and susceptible
48 individuals (Zhanel *et al.*, 2008; Rhomberg *et al.*, 2006; O'Brien *et al.*, 1999). Nikaido (2009)
49 mentioned that *Staphylococcus aureus* has a known nosocomial, multi-drug-resistant strain
50 referred to as the methicillin-resistant *Staphylococcus aureus* (MRSA). MRSA was initially
51 controlled but currently is also resistant to other antimicrobials like the aminoglycosides,
52 chloramphenicol, lincosamides, macrolides and tetracycline (McIntosh, 2018). This study was
53 conducted as part of evidence to buttress the efficacy of *Staphylococcal* infections in young
54 children and the scale to which MDR pathogens are becoming threats to the health of the
55 younger generation amongst the Mkpato Enin, Akwa-Ibom State populace.

56

57 **MATERIALS AND METHODS - sequentially number the references mentioned in this**
58 **section in square bracket after introduction; leave the space before mentioning of the units**

59

60 **Study Facility, Group and Sample Collection**

61 The study facility is in a growing town and services a couple of adjoining communities, with a
62 number of established institutions, stable commerce and ever growing population. The General
63 Hospital, Ikot-Ekpaw, in Mkpato Enin LGA, Akwa-Ibom State, South-South Nigeria, has Out-
64 patient department, Post-natal ward, Paediatric ward and servicing laboratories. The study
65 focused on children aged 1-15 years.

66 A hundred (100) sterile swabs samples from skin, nostrils, wound, throat and ear was sourced
67 over a period of three months. Once gotten, the swabs were labelled, placed in an ice pack and
68 taken to the Microbiology laboratory, Akwa-Ibom State University.

69 **Sample Analysis**

70 The sterile swab sticks were depth into peptone water and incubated at 37°C for 24 hours. A
71 loopful from each sample was streaked on separate Mannitol salt agar (MSA) plates and
72 incubated at 37°C for 24 hours. Discrete golden yellow colonies were subcultured, purified and
73 preserved. Only Gram positive cocci bacterial colonies were further tested for catalase and
74 coagulase.

75 **Antibiotics Susceptibility Test**

76 Confirmed *Staphylococcus aureus* isolates were tested for their susceptibilities to various
77 selected commercial antibiotic drugs like Ciprofloxacin, Erythromycin, Levofloxacin,
78 Gentamicin, Ampiclox, Rifampicin, Amoxicillin, Streptomycin, Norfloxacin and
79 Chloramphenicol. Overnight cultures using Kirby-Bauer method (Hudzicki, 2009) were
80 inoculated on Mueller-Hinton agar (Oxoid, Uk), cultures adjusted to 0.5 McFarland standard.
81 After pre-diffusion, the plates were inoculated at 37°C for 24 hours. Diameter of zones of
82 inhibition (IZDs) produced by the antibiotics were measured and recorded in millimeter.
83 Thereafter, the Multiple antibiotics resistance (MAR) index was determine for each isolate using
84 a formula $MAR = x/y$, where x is the number of antibiotics to which test isolate displayed
85 resistance and y is the total number of antibiotics to which the test organism has been evaluated
86 for sensitivity (Tula-Sanchez *et al.*, 2013; Olayinka *et al.*, 2004).

87 **RESULTS – combine discussion with this, leave the space before mentioning of the units**

88 Result for the prevalence of *S. aureus* is as shown in Table 1. The result table shows that of the
89 28 confirmed, wound samples had the highest number, which was followed by samples from
90 children skin swabs. The least number of confirmed *Staphylococcus aureus* isolates were from
91 the ear swabs.

92 The susceptibility pattern of the 28 confirmed test isolates to the selected commercially available
93 drugs (amoxicillin, ampiclox, chloramphenicol, ciprofloxacin, erythromycin, gentamicin,
94 levofloxacin, norfloxacin, rifampicin and streptomycin) is as shown in Figure 1. Ciprofloxacin
95 was the most effective drugs against the test organism, followed by Levofloxacin and

96 Norfloxacin. Confirmed *Staphylococcus aureus* isolates had high resistance for Amoxicillin,
 97 closely followed by their resistance for Ampiclox.

98

99

Table 1: Prevalence of *Staphylococcus aureus* from clinical samples

Type of Specimen	Sample Size	Number of <i>S. aureus</i> isolated	Total percentage
Skin	20	8	29
Nose	20	5	18
Wound	20	9	32
Throat	20	4	14
Ear	20	2	7

100




Figure 1: Antibiotics susceptibility pattern of *Staphylococcus* strains from clinical sample

101

102 **KEY:** R= Resistant, S= Sensitive, CPX= Ciprofloxacin, E= Erythromycin, LEV= Levofloxacin, CN= Gentamicin,
 103 APX= Ampiclox, RD= Rifampicin, AMX= Amoxicillin, S= Streptomycin, NB= Norfloxacin, CH=
 104 Chloramphenicol

105

106 Table 2 has the multiple antibiotics resistance (MAR) index result which shows that 85.7% of the
 107 confirmed test isolates were multi-drug resistant (showing resistance to three or more classes of
 108 antibiotics). Only 14.3% of the isolates showed resistance to only two classes of antibiotics.
 109 Results from this study show that 60.7% of test isolates had resistance for four or more
 110 antibiotics drugs. MAR index value for 96.4% of the test isolates reveal cases of source drug
 111 abuse.

Table 2: Antibiotic Resistance Pattern and MAR index of *Staphylococcus aureus*

S/N	ISOLATE CODE	Antibiotic Resistant Pattern	MARI	Antibiotic Resistant Class
1	S9	RD, S	0.2	RIF, AMG
2	S8	APX, AMX, CH	0.3	PEN, CHL
3	N3	LEV, APX, AMX	0.3	QUI, PEN
4	W1	CN, AMX, CH	0.3	AMG, PEN, CHL
5	W9	APX, AMX, S	0.3	PEN, AMG
6	S10	CN, APX, RD, AMX	0.4	AMG, PEN, RIF
7	T6	E, APX, AMX, NB	0.4	MAC, PEN, QUI
8	T8	CPX, E, APX, AMX	0.4	QUI, MAC, PEN
9	S2	E, APX, RD, AMX, S	0.5	MAC, PEN, RIF, AMG
10	S3	E, CN, APX, AMX, S	0.5	MAC, AMG, PEN
11	N1	E, CN, APX, AMX, CH	0.5	MAC, AMG, PEN, CHL
12	N2	CN, APX, AMX, S, CH	0.5	AMG, PEN, CHL
13	W2	E, LEV, APX, AMX, S	0.5	MAC, QUI, PEN, AMG
14	W5	E, APX, AMX, S, CH	0.5	MAC, PEN, AMG, CHL
15	W6	CN, APX, AMX, S, CH	0.5	AMG, PEN, CHL
16	W7	APX, AMX, S, NB, CH	0.5	PEN, AMG, QUI, CHL
17	W10	E, LEV, APX, AMX, S	0.5	MAC, QUI, PEN, AMG
18	T3	E, APX, AMX, S, CH	0.5	MAC, PEN, AMG, CHL
19	E5	E, CN, APX, RD, AMX	0.5	MAC, AMG, PEN, RIF
20	S1	E, CN, APX, RD, AMX, S	0.6	MAC, AMG, PEN, RIF
21	S5	E, LEV, APX, RD, AMX, S	0.6	MAC, QUI, PEN, RIF, AMG
22	S6	CN, APX, RD, AMX, S, CH	0.6	AMG, PEN, RIF, CHL
23	N5	CPX, CN, APX, AMX, S, CH	0.6	QUI, AMG, PEN, CHL
24	W8	E, CN, APX, AMX, S, NB	0.6	MAC, AMG, PEN, QUI
25	N8	E, CN, APX, RD, AMX, S, NB	0.7	MAC, AMG, PEN, RIF, QUI
26	W3	LEV, CN, APX, RD, AMX, S, NB	0.7	QUI, AMG, PEN, RIF
27	T2	E, CN, APX, RD, AMX, S, CH	0.7	MAC, AMG, PEN, RIF, CHL

KEY: CPX= Ciprofloxacin, E= Erythromycin, LEV= Levofloxacin, CN= Gentamicin, APX= Ampiclox, RD= Rifampicin, AMX= Amoxicillin, S= Streptomycin, NB= Norfloxacin, CH= Chloramphenicol, MARI= Multiple antibiotic resistance index, RIF= Rifamycins, AMG= Aminoglycosides, PEN= Penicillins, CHL= Chloramphenicol, MAC= Macrolides, QUI= Quinolones

112 **DISCUSSIONS AND CONCLUSION - combine discussion with result section, leave the**
113 **space before mentioning of the units; separate conclusion; sequentially number the**
114 **references mentioned in this section in square bracket continuously**

115

116 Data for isolate occurrence and confirmation showed that there were more confirmed
117 *staphylococcus* isolates from wound swab-samples, followed by skin sample-swabs. Parta *et al.*
118 (2009) also recorded very high *Staphylococcus* number from wound swabs. This high isolate-
119 numericals is suggestive of the exposed nature of the sampling points. This is supported by
120 findings presented by Nimmo *et al.* (2009), who found more *Staphylococcus* isolates on exposed
121 body surfaces than the internal parts. While uncovered wounds have sticky surfaces and the skin
122 is continuously exposed, it is therefore easy for such high microbial numbers to be recorded.

123 Susceptibility data showed that all the confirmed and tested isolates resisted two or more
124 antimicrobials. Qureshi *et al.* (2004) also isolated MRSA that resisted multiple anti-microbials
125 from hospital specimens. This study's result showed a higher MDR percentage than the "nearly
126 half" proportion reported by Nimmo *et al.* (2009).

127 More than 96.4% of the MAR indices were 0.3 from this study evaluation. This assertion is
128 indicative that resistance to these multiple drugs come from over exposure of the isolates to
129 drugs, making them adapt or resistant to them with recurrent treatments. The high case of MDR
130 amongst microorganisms can drastically be reduced by mere restricting the indiscriminate and
131 readily availability of these drugs over the counter (Nimmo *et al.*, 2009).

132 Many studies have shown that prolonged stays in hospitals increases the risk for colonization or
133 infection with MDR *Staphylococcus aureus*. This reflects an inherent risk in acquiring MDR
134 organisms through environmental contaminations and hospital stay conditions. With infant
135 patients, another potential transmission route is through infected staff members handling and this
136 calls for special care (Buke *et al.*, 2007; Maamar *et al.*, 2016).

137

138 The isolation of MDR *Staphylococcus aureus* from infant patients is a call for the proper
139 implementation of contact precautions during hospitalization especially in developing countries
140 (Harbarth *et al.*, 2006; Buke *et al.*, 2007).

141 **Ethical consideration**

142 The study was approved by the ministry of health, Akwa Ibom State (**Give the reference**
143 **no.**). Permission was obtained from General Administration of the General hospital prior to
144 collecting any data. Participants' privacy and confidentiality have been assured (no names have
145 been used, only numbers were used) and all data and results have been handled and treated
146 confidentially.

147

148 **REFERENCES – Continuously mention the references from introduction, method,**
149 **discussion**

150 Buke, C., Armand-Lefevre, L., Lolom, I., Guerinot, W., Deblangy, C., Ruimy, R., Andremont,
151 A. and Lucet J. C. (2007). Epidemiology of multidrug-resistant bacteria in patients with long
152 hospital stays. *Infection Control and Hospital Epidemiology*, 28(11):1255–1260.

153 Harbarth, S., Sax, H., Fankhauser-Rodriguez, C., Schrenzel, J., Agostinho, A. and Pittet, D.
154 (2006). Evaluating the probability of previously unknown carriage of MRSA at hospital
155 admission. *American Journal of Medicine* 119(3):275.e15-e23

156 Hudzicki, J. (2009). Kirby-Bauer disk diffusion susceptibility test protocol. *American Society for*
157 *Microbiology*, 23 pages.

158 Maamar, E., Ferjani, S., Jendoubi, A., Hammami, S., Hamzaoui, Z., Mayonnove-Coulangue, L.,
159 Saidani, M., Kammoun, A., Rehaïem, A., Ghedira, S., Houissa, M., Boutiba-Ben Boubaker, I.,
160 Slim, A. and Dubois, V. (2016). High prevalence of gut microbiota colonization with broad-
161 spectrum cephalosporin resistant enterobacteriaceae in a tunisian intensive care unit. *Frontiers in*
162 *Microbiology*, 7, 1859.

163

164 Magiorakos, A. P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G.,
165 Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., Paterson, D. L., Rice, I. B.,
166 Stelling, J., Struelens, M. J., Vatopoulos, A., Weber J. T. and Monnet, D. L. (2012). Multidrug-
167 resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert
168 proposal for interim standard definitions for acquired resistance. *Clinical Microbiology and*
169 *Infection*, 18, 268–281.

170 McIntosh, J. (2018). Antibiotic resistance: What you need to know. Medical news today,
171 (<https://www.medicalnewstoday.com/articles/283963.php>).

172 Nikaido, H. (2009). Multidrug Resistance in Bacteria. *Annual Review of Biochemistry*, 78, 119–
173 146.

174 Nimmo, G. R., Pearson, J. C., Collignon, P. J., Christiansen, K. J., Coombs, G. W., Bell, J. M.,
175 McLaws M. L. and the Australian Group on Antimicrobial Resistance (2011). Antimicrobial
176 susceptibility of *Staphylococcus aureus* isolated from hospital in-patient. *Community*
177 *Disease Intelligence*, 35(3):237–243.

178 O'Brien, F. G., Pearman, J. W., Gracey, M., Riley, T. V. and Grubb, W. B. (1999). Community
179 strain of methicillin-resistant *Staphylococcus aureus* involved in a hospital outbreak. *Journal of*
180 *Clinical Microbiology*, 37(9):2858–2862.

181 Olayinka, A. T., Onile, B. A. and Olayinka, B. O. (2004). Prevalence of multi-drug resistance
182 (MDR) *Pseudomonas aeruginosa* isolates in surgical units of Ahmadu Bello University
183 Teaching Hospital, Zaria, Nigeria: An indication for effective control measures. *Annals of*
184 *African Medicine* 3(1): 13-16.

185 Parta, M., Goebel, M., Matloobi, M., Stager, C. and Musher, D. M. (2009). Identification of
186 Methicillin-Resistant or Methicillin-Susceptible *Staphylococcus aureus* in Blood Cultures
187 and Wound Swabs by GeneXpert. *Journal of Clinical Microbiology*, 47(5):1609–1610.

188 Qureshi, A. H., Rafi, S., Qureshi, S. M. and Ali, A. M. (2004). The Current Susceptibility
189 Patterns of Methicillin Resistant *Staphylococcus aureus* to Conventional Anti-Staphylococcus
190 Antimicrobials at Rawalpindi. *Pakistan Journal of Medical Science*, 20(4): 361-364.

191 Rhomberg, P. R., Fristoche, T. R., Sader, H. S. and Jones, R. N. (2006). Antimicrobial
192 susceptibility pattern comparisons among intensive care unit and general ward Gram negative
193 isolates from meropenem yearly susceptibility test Information programme (USA). *Diagnostic*
194 *Microbial Infectious Disease*, 56, 57-62.

195 Singh, V. (2013). Antimicrobial resistance In: *Microbial Pathogens and Strategies for Combating*
196 *Them: Science, Technology and Education*, Formatex Research Center, 1,291-296.

197 Tanwar, J., Das, S., Zeeshan, F. and Hameed, S. (2014). Multidrug Resistance: An Emerging
198 Crisis. *Interdisciplinary Perspectives on Infectious Diseases*, 7 pages.

199 Tula-Sanchez, A. A., Havas, A. P., Alonge, P. J., Klein, M. E., Doctor, S. R., Pinkston, W.,
200 Glinsmann-Gibson, B. J., Rimsza, L. M. and Smith, C. (2013). A model of sensitivity and
201 resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-
202 dependent kinase inhibitors. *Cancer Biology and Therapy*, 14(10): 949-961.

203 WHO (2014). *Antimicrobial Resistance Global Report on Surveillance*. Geneva, Switzerland:
204 World Health Organization.

205 Zhanel, G. G., Corby, D., Laing, N., Weshionweski, B., Vashisht, R. and Tailer, F. (2008).
206 Canadian Antimicrobial Resistant Pathogens in Intensive care Unit (CAN-ICU) study 2005-
207 2006. *Antimicrobial Agents and Chemotherapy*, 52, 1430-1437.